{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:01:17Z","timestamp":1787724077532,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jdiacomp.2023.108456","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T21:53:56Z","timestamp":1679090036000},"page":"108456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of sodium glucose cotransporter 2 inhibitors plus standard care in diabetic kidney disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Louise M.","family":"Woodhams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tin Fei","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bu B.","family":"Yeap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus P.","family":"Schlaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham S.","family":"Hillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2023.108456_bb0005","first-page":"49","article-title":"Diabetic kidney disease: world wide difference of prevalence and risk factors","volume":"5","author":"Gheith","year":"2016","journal-title":"J Nephropharmacol."},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrneph.2010.58","article-title":"The RAAS in the pathogenesis and treatment of diabetic nephropathy","volume":"6","author":"Ruggenenti","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0025","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0030","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0035","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0040","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.2337\/dc20-S011","article-title":"11. Microvascular complications and foot care: standards of medical Care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0045","article-title":"Efficacy and safety of combination therapy with sodium-glucose transporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis","author":"Tian","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0050","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2169\/internalmedicine.9842-17","article-title":"The anticipated renoprotective effects of sodium-glucose cotransporter 2 inhibitors","volume":"57","author":"Ito","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0055","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0060","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/dom.13923","article-title":"The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis","volume":"22","author":"Scholtes","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0065","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2014070688","article-title":"Reducing albuminuria as surrogate endpoint C. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis","volume":"26","author":"Heerspink","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0070","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/HJH.0000000000002050","article-title":"The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Piperidou","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0075","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0080","series-title":"The Cochrane Collaboration","article-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]","year":"2011"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107590","article-title":"Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - a double blind randomized placebo-controlled crossover trial","volume":"34","author":"Eickhoff","year":"2020","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0100","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0105","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/dom.12936","article-title":"The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients","volume":"19","author":"Petrykiv","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfz103.SP085","article-title":"SP085 use of sodium-glucose co-transporter 2 (SGLT2) inhibitor in patients with diabetes mellitus free chronic kidney disease 2\u20133a stages: 1 year of experience","volume":"34","author":"Ivanov","year":"2019","journal-title":"Nephrol Dial Transplantat"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0120","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0125","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1479164118782872","article-title":"Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: a randomized open-label prospective trial","volume":"15","author":"Takashima","year":"2018","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0130","article-title":"24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study","author":"Kario","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0135","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0140","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/jdi.12971","article-title":"Empagliflozin and kidney outcomes in asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME((R)) trial","volume":"10","author":"Kadowaki","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0145","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)\u2013a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, design and baseline characteristics of the CANagliflozin cardioVascular assessment study-renal (CANVAS-R): a randomized, placebo-controlled trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.15","article-title":"Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes","volume":"1","author":"Nunoi","year":"2018","journal-title":"Endocrinol Diabetes Metab."},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0160","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/dia.2018.0169","article-title":"Effect of canagliflozin on urinary albumin excretion in japanese patients with type 2 diabetes mellitus and microalbuminuria: a pilot study","volume":"20","author":"Osonoi","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0165","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0170","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0175","series-title":"International Encyclopedia of Public Health","author":"Tatsioni","year":"2017"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0185","unstructured":"AstraZeneca . Significant advancement in chronic kidney disease (CKD) treatment with TGA approval of Forxiga (Dapagliflozin). https:\/\/www.astrazeneca.com.au\/media\/press-releases\/2021\/significant-advancement-in-chronic-kidney-disease.html#! Published 2021. Accessed 14\/02\/2022."},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0190","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0195","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0200","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0205","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0210","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0215","unstructured":"AstraZeneca. Forxiga approved in the EU for the treatment of chronic kidney disease in patients with and without type-2 diabetes. https:\/\/bit.ly\/3lXr8Bm. Published 2021. Accessed 18\/01\/2022."},{"key":"10.1016\/j.jdiacomp.2023.108456_bb0220","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(21)01242-3","article-title":"FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?","volume":"398","author":"Jafar","year":"2021","journal-title":"Lancet"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723000545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723000545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:16:39Z","timestamp":1761005799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872723000545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1056872723000545"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108456","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of sodium glucose cotransporter 2 inhibitors plus standard care in diabetic kidney disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108456"}}